Amerikanische Gesellschaft für Hirudotherapie

Anticoagulation during ECMO in neonatal and paediatric patients.

Review published in Thrombosis research (2018)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungBarton et al. · Thrombosis research, 2018

Abstract

Extracorporeal Membrane Oxygenation (ECMO) is a form of Extracorporeal Life Support (ECLS) which is used frequently in the paediatric and neonatal setting to support either the pulmonary, or both the pulmonary and cardiac systems. Management of ECMO requires the use of systemic anticoagulation to prevent patient and circuit based thrombosis, which in turn increases the risk of haemorrhage. A number of coagulation tests, laboratory and point of care based, are used to monitor anticoagulation, however the evidence for correlation of the test results with level of anticoagulant and clinical outcomes in children remains poor.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Coagulation TestsChildDrug MonitoringExtracorporeal Membrane OxygenationHemorrhageHemostasisHumansInfantThrombosis

Zusammenfassung

Extracorporeal Membrane Oxygenation (ECMO) is a form of Extracorporeal Life Support (ECLS) which is used frequently in the paediatric and neonatal setting to support either the pulmonary, or both the pulmonary and cardiac systems. Management of ECMO requires the use of systemic anticoagulation to...

Warum dies für die Hirudotherapie relevant ist

This review discussed the use of systemic anticoagulation and the challenges of monitoring its therapeutic effects during extracorporeal membrane oxygenation in pediatric and neonatal patients, noting that evidence for correlation between coagulation test results and clinical outcomes in children remains poor. The abstract addresses the clinical tension between preventing thrombosis and increasing hemorrhage risk in this critical care setting. It does not mention leeches, hirudotherapy, hirudin, or any leech-derived substances. Based solely on this abstract, there is no defensible connection to ASH's domain.

Zitation

Anticoagulation during ECMO in neonatal and paediatric patients.

Barton et al. · Thrombosis research, 2018

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsMicrosurgery OutcomesSurgeryAnticoagulation CompoundsHemostasisCardiovascularCardiologyPediatricsOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.